Abstract |
Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct acting antiviral therapies. A yeast-based immunotherapy (Tarmogen) platform was used to make a vaccine candidate expressing hepatitis B virus (HBV) X, surface (S), and Core antigens (X-S-Core). Murine and human immunogenicity models were used to evaluate the type and magnitude of HBV-Ag specific T cell responses elicited by the vaccine. C57BL/6J, BALB/c, and HLA-A*0201 transgenic mice immunized with yeast expressing X-S-Core showed T cell responses to X, S and Core when evaluated by lymphocyte proliferation assay, ELISpot, intracellular cytokine staining (ICS), or tumor challenge assays. Both CD4+ and CD8+ T cell responses were observed. Human T cells transduced with HBc18-27 and HBs183-91 specific T cell receptors (TCRs) produced interferon gamma (IFNγ following incubation with X-S-Core-pulsed dendritic cells (DCs). Furthermore, stimulation of peripheral blood mononuclear cells (PBMCs) isolated from CHB patients or from HBV vaccine recipients with autologous DCs pulsed with X-S-Core or a related product (S-Core) resulted in pronounced expansions of HBV Ag-specific T cells possessing a cytolytic phenotype. These data indicate that X-S-Core-expressing yeast elicit functional adaptive immune responses and supports the ongoing evaluation of this therapeutic vaccine in patients with CHB to enhance the induction of HBV-specific T cell responses.
|
Authors | Thomas H King, Charles B Kemmler, Zhimin Guo, Derrick Mann, Yingnian Lu, Claire Coeshott, Adam J Gehring, Antonio Bertoletti, Zi Z Ho, William Delaney, Anuj Gaggar, G Mani Subramanian, John G McHutchison, Shikha Shrivastava, Yu-Jin L Lee, Shyamasundaran Kottilil, Donald Bellgrau, Timothy Rodell, David Apelian |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 7
Pg. e101904
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25051027
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hepatitis B Vaccines
- Interleukin-2
- Trans-Activators
- Viral Core Proteins
- Viral Fusion Proteins
- Viral Regulatory and Accessory Proteins
- hepatitis B virus X protein
- Interferon-gamma
|
Topics |
- Animals
- Cell Proliferation
- Cells, Cultured
- Cross-Priming
- Dendritic Cells
(immunology, virology)
- Female
- Hepatitis B Vaccines
(immunology)
- Hepatitis B virus
(immunology)
- Hepatitis B, Chronic
(immunology, prevention & control, virology)
- Humans
- Interferon-gamma
(metabolism)
- Interleukin-2
(metabolism)
- Liver Neoplasms
(virology)
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, SCID
- Saccharomyces cerevisiae
(genetics)
- T-Lymphocytes
(immunology, virology)
- Trans-Activators
(genetics, immunology)
- Vaccination
- Viral Core Proteins
(genetics, immunology)
- Viral Fusion Proteins
(genetics, immunology)
- Viral Regulatory and Accessory Proteins
|